Evicenter
P&T meetings

Atebrioz

Fibrodysplasia ossificans progressiva

Also known as zilurgisertib, INCB000928
Regulatory submission
NDA submitted by May 2026
96 sources

Section 6 of 6

References

96 sources

  1. Acikgoz et al. (2026) (opens in a new tab)
  2. Al Mukaddam et al. (2022) (opens in a new tab)
  3. Atebrioz Prescribing Information (2026) (opens in a new tab)
  4. Baujat et al. (2017) (opens in a new tab)
  5. Baujat et al. (2026) (opens in a new tab)
  6. BioPharma Dive (2023) (opens in a new tab)
  7. BioPharma Dive (2026) (opens in a new tab)
  8. BioSpace (2026) (opens in a new tab)
  9. Bose et al. (2025) (opens in a new tab)
  10. Botman et al. (2021) (opens in a new tab)
  11. Cacco et al. (2025) (opens in a new tab)
  12. CADTH Pharmacoeconomic Review (2023) (opens in a new tab)
  13. CADTH Pharmacoeconomic Review (2023) (opens in a new tab)
  14. CADTH Pharmacoeconomic Review (2023) (opens in a new tab)
  15. CADTH Reimbursement Recommendation (2023) (opens in a new tab)
  16. Chen et al. (2020) (opens in a new tab)
  17. ClinicalTrials.gov NCT04307953 (opens in a new tab)
  18. ClinicalTrials.gov NCT04455841 (opens in a new tab)
  19. ClinicalTrials.gov NCT04455841 (opens in a new tab)
  20. ClinicalTrials.gov NCT04582539 (opens in a new tab)
  21. ClinicalTrials.gov NCT04582539 (opens in a new tab)
  22. ClinicalTrials.gov NCT05039515 (opens in a new tab)
  23. ClinicalTrials.gov NCT05090891 (opens in a new tab)
  24. ClinicalTrials.gov NCT05099445 (opens in a new tab)
  25. ClinicalTrials.gov NCT05394116 (opens in a new tab)
  26. ClinicalTrials.gov NCT06089616 (opens in a new tab)
  27. ClinicalTrials.gov NCT06508021 (opens in a new tab)
  28. Di Rocco et al. (2023) (opens in a new tab)
  29. European Medicines Agency (2023) (opens in a new tab)
  30. European Medicines Agency (2025) (opens in a new tab)
  31. FDA (2026) (opens in a new tab)
  32. FDA Novel Drug Approvals (2026) (opens in a new tab)
  33. Fierce Pharma (2026) (opens in a new tab)
  34. Gaechter et al. (2026) (opens in a new tab)
  35. Harrak et al. (2025) (opens in a new tab)
  36. Hatsell et al. (2015) (opens in a new tab)
  37. Hino et al. (2015) (opens in a new tab)
  38. Hsiao and Pacifici (2025) (opens in a new tab)
  39. Hsiao et al. (2019) (opens in a new tab)
  40. IFOPA (opens in a new tab)
  41. IFOPA Mirum FAQs (2026) (opens in a new tab)
  42. IFOPA zilurgisertib announcement (2026) (opens in a new tab)
  43. Incyte Corporation INCB 00928-104 protocol (2025) (opens in a new tab)
  44. Incyte Corporation INCB 00928-104 statistical analysis plan (2025) (opens in a new tab)
  45. Incyte Corporation INCB 00928-105 statistical analysis plan (2024) (opens in a new tab)
  46. Incyte Form 10-K (2026) (opens in a new tab)
  47. Incyte Form 10-Q (2026) (opens in a new tab)
  48. International Clinical Council on FOP (2025) (opens in a new tab)
  49. International Clinical Council on FOP classes of medications (2024) (opens in a new tab)
  50. International Clinical Council on FOP current treatment considerations (2024) (opens in a new tab)
  51. International Clinical Council on FOP executive summary (2025) (opens in a new tab)
  52. Ipsen (2025) (opens in a new tab)
  53. Ipsen (2026) (opens in a new tab)
  54. Kaplan et al. (2010) (opens in a new tab)
  55. Kaplan et al. (2018) (opens in a new tab)
  56. Kaplan et al. (2025a) (opens in a new tab)
  57. Kaplan et al. (2025b) (opens in a new tab)
  58. Keen et al. (2024) (opens in a new tab)
  59. Kitterman et al. (2005) (opens in a new tab)
  60. MedCity News (2026) (opens in a new tab)
  61. Mirum Access Plus (2026) (opens in a new tab)
  62. Mirum Pharmaceuticals (2026) (opens in a new tab)
  63. Mirum Pharmaceuticals first-quarter 2026 results (2026) (opens in a new tab)
  64. Mirum Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  65. Mirum Pharmaceuticals PROGRESS results press release (2026) (opens in a new tab)
  66. Mohan et al. (2023) (opens in a new tab)
  67. NICE (2025) (opens in a new tab)
  68. NIHR Innovation Observatory (2025) (opens in a new tab)
  69. Ortiz-Agapito et al. (2015) (opens in a new tab)
  70. Pasatru Prescribing Information (2026) (opens in a new tab)
  71. Peng et al. (2019) (opens in a new tab)
  72. Pignolo and Kaplan (2018) (opens in a new tab)
  73. Pignolo et al. (2016) (opens in a new tab)
  74. Pignolo et al. (2019) (opens in a new tab)
  75. Pignolo et al. (2020) (opens in a new tab)
  76. Pignolo et al. (2021) (opens in a new tab)
  77. Pignolo et al. (2022a) (opens in a new tab)
  78. Pignolo et al. (2022b) (opens in a new tab)
  79. Pignolo et al. (2023a) (opens in a new tab)
  80. Pignolo et al. (2023b) (opens in a new tab)
  81. Pignolo et al. (2026a) (opens in a new tab)
  82. Pignolo et al. (2026b) (opens in a new tab)
  83. Pignolo et al. (2026c) (opens in a new tab)
  84. Reuters (2026) (opens in a new tab)
  85. Shore et al. (2006) (opens in a new tab)
  86. Smilde et al. (2022) (opens in a new tab)
  87. Sohonos Prescribing Information (2026) (opens in a new tab)
  88. Swain (2026) (opens in a new tab)
  89. Ullrich et al. (2025) (opens in a new tab)
  90. Xu et al. (2025) (opens in a new tab)
  91. Xun et al. (2022a) (opens in a new tab)
  92. Xun et al. (2022b) (opens in a new tab)
  93. Yang et al. (2025a) (opens in a new tab)
  94. Yang et al. (2025b) (opens in a new tab)
  95. Yang et al. (2026a) (opens in a new tab)
  96. Yang et al. (2026b) (opens in a new tab)